论文部分内容阅读
目的:观察达英-35联合吡格列酮促进多囊卵巢综合症患者的排卵效果。方法:90例PCOS患者随机分为治疗组和对照组各45例,对照组口服达英-35,治疗组加服吡格列酮,3个疗程后对比疗效。结果:治疗后治疗组的排卵率和妊娠成功率均高于对照组,差异均有统计学意义(P<0.05);治疗组的LH和FINS均低于对照组,差异均有统计学意义(P<0.05)。结论:达英-35联合吡格列酮能明显提高PCOS患者的排卵率和妊娠成功率,值得临床应用。
OBJECTIVE: To observe the ovulation effect of Dayang-35 combined with pioglitazone in patients with polycystic ovary syndrome. Methods: Ninety PCOS patients were randomly divided into treatment group (45 cases) and control group (45 cases). The control group was treated with da-Ying -35. The patients in the treatment group were given pioglitazone. After 3 cycles of treatment, the curative effect was compared. Results: After treatment, the ovulation rate and pregnancy success rate of the treatment group were higher than those of the control group (P <0.05). The LH and FINS of the treatment group were lower than those of the control group (P <0.05), the differences were statistically significant P <0.05). Conclusion: The combination of da-Ying-35 and pioglitazone can significantly improve the ovulation rate and pregnancy success rate in PCOS patients, which is worthy of clinical application.